BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Up 5.5% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a biopharmaceutical company specializing in therapies for rare genetic diseases, including enzyme replacement and gene therapy. Today, the stock had a strong bullish movement in the market.

Why is BioMarin Pharmaceutical Inc. going up?

BMRN stock is up 5.5% on Jun 1, 2026 13:40

• The company saw a bullish movement after the positive Phase 3 study results for its drug VOXZOGO, leading to plans for a supplemental New Drug Application.
• Reinstatement of coverage on large-cap biotechnology companies, with positive sentiments towards the sector by a prominent financial institution, likely contributed to the bullish trend in BMRN's stock.
• Analysts' revised revenue guidance and fair value estimates, along with discussions on the company's valuation post-positive trial results, provided further confidence in BMRN's growth potential amidst competitive dynamics.
• The market's optimism towards BMRN's future, despite concerns about long-term prospects and competitive pressures, reflects a mix of growth opportunities and caution among analysts, ultimately driving the bullish movement in the stock.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

5 Stocks That Could 10X by 2030

This article lists five stocks with the potential to increase tenfold by 2030, with BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) being the first discussed. BioMarin recently reported positive Phase 3 study results for its drug VOXZOGO, prompting intentions to submit a supplemental New Drug Application to regulatory bodies. The company specializes in therapies for rare genetic diseases, including enzyme replacement and gene therapy.

https://www.insidermonkey.com/blog/5-stocks-that-could-10x-by-2030-1770616/

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, indicating a significant upturn for the sector. The bank believes these companies are reaching a critical inflection point, with successful pipelines translating into profitable and diverse commercial enterprises. Several firms received "Overweight" ratings due to expanding product portfolios, strong clinical pipelines, and potential business development, while Moderna received an "Underweight" rating.

https://m.investing.com/news/stock-market-news/jpmorgan-says-largecap-biotech-is-back-as-profits-and-pipelines-fuel-upside-4715304?ampMode=1

BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead

AnalystConsensusTarget has updated its fair value estimate for BioMarin Pharmaceutical (BMRN) to $89.96, reflecting revised assumptions on various financial metrics and a blend of recent analyst price target adjustments. The company's future is influenced by the planned Amicus acquisition, potential Voxzogo indication expansions, and pipeline developments, all while navigating competitive pressures and recent trial discontinuations. There's a divide among analysts, with some highlighting growth opportunities and others expressing caution regarding Voxzogo's long-term prospects amidst rising competition.

https://simplywall.st/narratives/lfwega1e-bmrn-revenue-guidance-revision-will-reveal-new-competitive-dynamics-ahead?bpId=4599143&link_type=cta_narrative_prompt_after_quote

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results

BioMarin Pharmaceutical (BMRN) valuation is in focus following positive Phase 3 trial results for its drug Voxzogo. While the company's shares have seen a short-term rally, longer-term returns remain weak. Analysts currently value BMRN as 41.2% undervalued, indicating potential for growth despite competitive pressure and acquisition costs.

https://www.sahmcapital.com/news/content/a-look-at-biomarin-pharmaceutical-bmrn-valuation-after-positive-voxzogo-phase-3-trial-results-2026-05-27

Trending Today

Paycom Software Inc. ($PAYC) Stock Forecast: Up 5.0% Today

CDW Corporation ($CDW) Stock Forecast: Up 5.2% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 4.3% Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.2% Today

BlackRock Inc. ($BLK) Stock Forecast: Down 1.9% Today

Chipotle Mexican Grill Inc. ($CMG) Stock Forecast: Down 2.8% Today

Datadog Inc. ($DDOG) Stock Forecast: Up 5.2% Today

Archer-Daniels-Midland Company ($ADM) Stock Forecast: Up 2.1% Today

Old Dominion Freight Line Inc. ($ODFL) Stock Forecast: Up 3.4% Today

Intercontinental Exchange Inc. ($ICE) Stock Forecast: Down 2.9% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

21.04.2026 - BMRN Stock was up 6.6%

• The bullish movement in BMRN stock can be attributed to the positive Phase 3 pivotal study results for VOXZOGO in children with hypochondroplasia. Meeting its primary endpoint with significant improvements in annualized growth velocity and other key measures has generated positive investor sentiment.
• Despite the mixed outcomes from the Phase 1/2 study of BMN 351 for Duchenne muscular dystrophy, which led to a decline in stock price, the company's decision to continue with the higher dose in future trials could have provided some reassurance to investors.
• The overall positive sentiment surrounding BioMarin's successful trials and potential new drug applications has likely overshadowed concerns raised in the SWOT analysis, contributing to the bullish movement in the stock today.

29.04.2026 - BMRN Stock was up 5.1%

• BMRN's stock surged on favorable Phase 3 results for its medication Voxzogo, designed to treat children with hypochondroplasia a rare genetic disorder affecting bone growth.
• The successful meeting of the primary trial goal for Voxzogo, which displayed a noteworthy rise in annualized growth velocity in patients, has instilled confidence and optimism among investors regarding the company's future.
• Analysts have adjusted their fair value projection for BMRN, underscoring the potential benefits of the forthcoming Amicus acquisition, growth avenues for Voxzogo, and overall pipeline advancements, while acknowledging worries about competitive forces and recent trial halts.
• The encouraging Voxzogo study outcome not only affirms the drug's effectiveness but also underscores BioMarin's dedication to addressing medical needs, leading to the positive market movement of its stock.

21.04.2026 - BMRN Stock was up 5.1%

• Positive Phase 3 pivotal study results for VOXZOGO in children with hypochondroplasia, demonstrating significant improvements in growth velocity and other key metrics, fueled investor optimism and drove the bullish movement.
• BioMarin's plans to submit a supplemental New Drug Application to regulatory authorities in the near future added to the positive sentiment surrounding the stock.
• Despite facing competitive headwinds and setbacks in other clinical studies, the successful results from the VOXZOGO trial overshadowed these concerns and contributed to the stock's surge.
• Analyst downgrades and uncertainties mentioned in the SWOT analysis did not seem to impact the market movement significantly, as the positive trial data took the spotlight and drove the stock price higher.

24.01.2026 - BMRN Stock was down 5.5%

• BioMarin posted strong Q4 revenue surpassing forecasts and a positive full-year 2025 performance. However, the stock witnessed a bearish trend possibly due to falling short of analyst predictions on non-GAAP EPS and adjusted EBITDA.
• The FDA's rejection of BioMarin's gene therapy for hemophilia A, delaying its potential market launch, might have impacted the negative investor sentiment on the company's future revenue prospects.
• An AI analysis indicating a bleak long-term outlook and increased downside risk for BioMarin could have also influenced the downward pressure on the stock.
• In conclusion, the combination of financial performance lagging expectations and regulatory obstacles could have contributed to the bearish movement of BioMarin's stock today.

18.02.2026 - BMRN Stock was down 5.4%

• The halt of mid-stage trials for the bone disorder treatment, Voxzogo, due to safety concerns like hip joint slippage in patients, led to a 4% drop in BioMarin's shares.
• The discontinuation of dosing and enrollment in Phase 2 trials for Voxzogo targeting various disorders due to slipped capital femoral epiphysis (SCFE) events introduced uncertainty and negatively impacted the stock.
• The competition in the achondroplasia indication, with the FDA approval of Ascendis Pharma's Yuviwel, added pressure on BioMarin as it halted studies for certain disorders, affecting investor confidence and contributing to the bearish movement.
• Despite being considered a compelling value investment opportunity with strong financial health and profitability metrics, the negative developments in the Voxzogo trials overshadowed the potential growth prospects, resulting in the stock's decline.

19.01.2026 - BMRN Stock was up 5.1%

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

01.05.2026 - BMRN Stock was up 5.5%

• The company saw a bullish movement after the positive Phase 3 study results for its drug VOXZOGO, leading to plans for a supplemental New Drug Application.
• Reinstatement of coverage on large-cap biotechnology companies, with positive sentiments towards the sector by a prominent financial institution, likely contributed to the bullish trend in BMRN's stock.
• Analysts' revised revenue guidance and fair value estimates, along with discussions on the company's valuation post-positive trial results, provided further confidence in BMRN's growth potential amidst competitive dynamics.
• The market's optimism towards BMRN's future, despite concerns about long-term prospects and competitive pressures, reflects a mix of growth opportunities and caution among analysts, ultimately driving the bullish movement in the stock.

27.01.2026 - BMRN Stock was up 5.2%

• Concerns may have initially arisen from the EVP's stock sale, but investors did not seem discouraged by this insider activity.
• The decision to halt the hemophilia gene therapy, Roctavian, due to underwhelming sales could have been seen as a strategic choice to minimize losses and focus on more promising ventures.
• BioMarin's increased efforts in business development amidst rising competition for Voxzogo could have raised investors' optimism about the company's ability to navigate challenges and stay competitive.
• Participation in upcoming investor conferences and a positive Q4 earnings report, surpassing expectations in both earnings and revenue, likely played a role in boosting the positive sentiment surrounding BioMarin's stock today.

10.01.2026 - BMRN Stock was up 5.0%

• BMRN saw an upward trend today following positive analyst ratings and price target increases from various firms, including Piper Sandler, Barclays, and Canaccord Genuity.
• Factors such as the impending acquisition of Amicus Therapeutics and the upcoming data release for its experimental therapy INZ-701 have contributed to the positive outlook surrounding BMRN.
• Analysts view BMRN as undervalued with significant growth potential, anticipating revenue escalation and profit margin enhancement in the coming years.
• The company's strategic acquisitions and dedication to rare disease treatments have bolstered investor confidence, driving the bullish market performance.

12.01.2026 - BMRN Stock was up 1.1%

• Despite anticipated Q4 earnings decline, BioMarin Pharmaceutical (BMRN) saw an upward trend, reflecting investor confidence in its long-term prospects.
• Favorable ratings from analysts, adjustments in price targets, and excitement surrounding the impending acquisition of Amicus Therapeutics have contributed to the positive outlook for BMRN.
• The upcoming crucial data release for the experimental therapy INZ-701, designed for treating ENPP1 Deficiency, stands as a significant driver for BioMarin's presence in the rare disease market and likely heightened investor confidence.
• The generally optimistic sentiment towards BMRN, supported by promising forecasts, analyst support, and forthcoming catalysts, has outweighed worries about the projected earnings decline for the quarter.

05.04.2026 - BMRN Stock was up 0.8%

• BioMarin Pharmaceutical (BMRN) experienced a strong bullish movement today following the release of its Q1 2026 earnings report and conference call.
• The company reported Q1 revenues of $766 million and raised its full-year revenue guidance, driven by the acquisition of Amicus and strong performance of key therapies.
• Despite falling short of analyst expectations on adjusted EPS for Q1, the market reacted positively to the increased revenue outlook and strategic acquisitions.
• The presentation of new data on the efficacy of Voxzogo in treating achondroplasia also contributed to the positive sentiment surrounding BioMarin Pharmaceutical, showcasing the company's commitment to advancing treatments for rare diseases.